Gilbert Cisneros, Representative
sell disclosed on 4 Sept 2026 via House STOCK Act disclosures
- Transaction value
- US$15,001
- Copy Window
- Be careful chasing
- Data Confidence
- 93%
- Previous signal outcome
- Not available
Public company research profile
This public-disclosure research profile is not investment advice. It summarizes historical public filings, source links, confidence context, and hypothetical outcomes so readers can verify the evidence themselves.
Company research history
17 Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)
Source-transparent disclosure history for this company, built from public CopyWindow signals and previous hypothetical outcomes.
6 disclosures
2 insiders
0 cluster signals
+10.2% avg. 30d outcome (5 of 6)
Company facts
- Ticker / ISIN
- CRNX / Not available
- Exchange
- Not available
- Country
- US
- Sector
- Not available
Disclosure history
Gilbert Cisneros, Representative
buy disclosed on 7 Apr 2026 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +13.2%
Gilbert Cisneros, Representative
buy disclosed on 6 May 2025 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +5.9%
Josh Gottheimer, Representative
sell disclosed on 10 Apr 2025 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +24.1%
Gilbert Cisneros, Representative
buy disclosed on 11 Feb 2025 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +0.3%
Josh Gottheimer, Representative
buy disclosed on 3 Oct 2024 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +7.7%